肝细胞癌射频消融与肝切除术的疗效比较：一项荟萃分析。

Efficacy comparison of radiofrequency ablation and hepatic resection for hepatocellular carcinoma: A meta-analysis.

作者信息

Changyong E, Wang Dan, Yu Yang, Liu Hongyu, Ren Hui, Jiang Tao

机构信息

Department of Hepatopancreatobiliary Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, China.

Department of Breast Surgery, The Second Hospital of Jilin University, Changchun 130041, China.

出版信息

J Cancer Res Ther. 2017;13(4):625-630. doi: 10.4103/jcrt.JCRT_406_17.

DOI:10.4103/jcrt.JCRT_406_17

PMID:28901304

Abstract

OBJECTIVES

The objective of this study is to compare the therapeutic efficacy of radiofrequency ablation (RFA) and hepatic resection (HR) for the treatment of hepatocellular carcinoma (HCC).

MATERIALS AND METHODS

A literature search was performed for comparative studies reporting outcomes of both RFA and HR for HCC. Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated.

RESULTS

A total of 4812 patients with HCC were included, with 2419 in the RFA group and 2393 in the HR group. The 3- and 5-year overall survival rates in the HR group were significantly higher than those in the RFA group (OR: 0.68, 95% CI: 0.58-0.79, P < 0.00001; OR: 0.57, 95% CI: 0.50-0.65, P < 0.00001, respectively). 1-, 3-, 5-year disease-free survival and correspond recurrence-free survival rates were all better in HR group.

CONCLUSION

RFA gets promising clinical outcomes for HCC treatments but is not yet comparable to surgery. HR is still the first-line treatment for HCC.

摘要

目的

本研究旨在比较射频消融（RFA）与肝切除术（HR）治疗肝细胞癌（HCC）的疗效。

材料与方法

对报告RFA和HR治疗HCC结果的比较研究进行文献检索。计算合并比值比（OR）及95%置信区间（95%CI）。

结果

共纳入4812例HCC患者，其中RFA组2419例，HR组2393例。HR组的3年和5年总生存率显著高于RFA组（OR分别为0.68，95%CI：0.58 - 0.79，P < 0.00001；OR为0.57，95%CI：0.50 - 0.65，P < 0.00001）。HR组的1年、3年、5年无病生存率及相应的无复发生存率均更好。